AU2009307841B2 - Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment - Google Patents

Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment Download PDF

Info

Publication number
AU2009307841B2
AU2009307841B2 AU2009307841A AU2009307841A AU2009307841B2 AU 2009307841 B2 AU2009307841 B2 AU 2009307841B2 AU 2009307841 A AU2009307841 A AU 2009307841A AU 2009307841 A AU2009307841 A AU 2009307841A AU 2009307841 B2 AU2009307841 B2 AU 2009307841B2
Authority
AU
Australia
Prior art keywords
val
ser
gly
leu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009307841A
Other languages
English (en)
Other versions
AU2009307841A1 (en
Inventor
Ling Liu
Haijun Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImClone LLC
Original Assignee
ImClone LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImClone LLC filed Critical ImClone LLC
Publication of AU2009307841A1 publication Critical patent/AU2009307841A1/en
Application granted granted Critical
Publication of AU2009307841B2 publication Critical patent/AU2009307841B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2009307841A 2008-10-20 2009-10-15 Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment Ceased AU2009307841B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19685508P 2008-10-20 2008-10-20
US61/196,855 2008-10-20
PCT/US2009/060840 WO2010048026A2 (en) 2008-10-20 2009-10-15 Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment

Publications (2)

Publication Number Publication Date
AU2009307841A1 AU2009307841A1 (en) 2010-04-29
AU2009307841B2 true AU2009307841B2 (en) 2013-09-12

Family

ID=42062445

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009307841A Ceased AU2009307841B2 (en) 2008-10-20 2009-10-15 Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment

Country Status (17)

Country Link
US (3) US8043618B2 (cg-RX-API-DMAC7.html)
EP (1) EP2342232A2 (cg-RX-API-DMAC7.html)
JP (1) JP5577345B2 (cg-RX-API-DMAC7.html)
KR (1) KR101370798B1 (cg-RX-API-DMAC7.html)
CN (2) CN103524620A (cg-RX-API-DMAC7.html)
AR (1) AR073770A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009307841B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0919832A8 (cg-RX-API-DMAC7.html)
CA (1) CA2741127C (cg-RX-API-DMAC7.html)
EA (1) EA021584B1 (cg-RX-API-DMAC7.html)
IL (1) IL211807A0 (cg-RX-API-DMAC7.html)
MX (1) MX2011004317A (cg-RX-API-DMAC7.html)
NZ (1) NZ592369A (cg-RX-API-DMAC7.html)
TW (1) TWI381848B (cg-RX-API-DMAC7.html)
UA (1) UA101681C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010048026A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201101938B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI381848B (zh) * 2008-10-20 2013-01-11 Imclone Llc 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物
PE20120553A1 (es) 2009-03-25 2012-05-18 Genentech Inc Anticuerpos anti-fgfr3
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
EA201591324A1 (ru) 2013-01-16 2016-01-29 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
MX2015011428A (es) 2013-03-06 2016-02-03 Genentech Inc Metodos para tratar y prevenir la resistencia a los farmacos para el cancer.
TWI541022B (zh) * 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體-3(fgfr3)之化合物及治療方法
WO2015148708A1 (en) 2014-03-25 2015-10-01 Regeneron Pharmaceuticals, Inc. Fgf21 receptor agonists and uses thereof
WO2015187521A2 (en) * 2014-06-03 2015-12-10 Merck Sharp & Dohme Corp. Anti-blys antibodies
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
EP3189341A4 (en) * 2014-09-05 2018-05-02 Hyperfine Research Inc. Ferromagnetic augmentation for magnetic resonance imaging
HUE058219T2 (hu) 2014-09-26 2022-07-28 Janssen Pharmaceutica Nv FGFR-mutánsgénpanel alkalmazása olyan rákbetegek azonosításában, akik FGFR-inhibitorral történõ kezelésre reszponzívak lesznek
CN107635583A (zh) * 2015-02-19 2018-01-26 生物临床医疗公司 用于治疗癌症的方法、组合物和试剂盒
EP3265462A1 (en) 2015-03-03 2018-01-10 INSERM - Institut National de la Santé et de la Recherche Médicale Fgfr3 antagonists
TW201711702A (zh) * 2015-06-04 2017-04-01 應克隆公司 使用針對纖維母細胞生長因子受體3(fgfr3)之化合物的療法
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
EP3481859B1 (en) 2016-07-07 2022-04-13 Pfizer Inc. Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof
US20180244785A1 (en) * 2017-01-09 2018-08-30 Merrimack Pharmaceuticals, Inc. Anti-fgfr antibodies and methods of use
US11505611B2 (en) 2020-08-21 2022-11-22 Genzyme Corporation FGFR3 antibodies and methods of use
CN114015770B (zh) * 2021-12-30 2022-04-26 佛山市第三人民医院(佛山市精神卫生中心) 精神分裂全外周血rna标志物fgfr3及其应用
EP4619438A2 (en) * 2022-11-14 2025-09-24 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
WO2024152014A1 (en) 2023-01-13 2024-07-18 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102973A2 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0318554B2 (en) 1987-05-21 2005-01-12 Micromet AG Targeted multifunctional proteins
US20070248605A1 (en) * 2003-12-19 2007-10-25 Five Prime Therapetutics, Inc. Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
EP2024394B1 (en) * 2006-06-06 2014-11-05 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
HRP20130163T1 (hr) * 2006-09-07 2013-03-31 Crucell Holland B.V. Ljudske molekule za vezanje koje mogu neutralizirati virus influence h5n1 i njihova uporaba
WO2009054873A2 (en) * 2007-08-02 2009-04-30 Novimmune S.A. Anti-rantes antibodies and methods of use thereof
KR102269708B1 (ko) * 2008-04-11 2021-06-25 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2313435A4 (en) * 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
TWI381848B (zh) * 2008-10-20 2013-01-11 Imclone Llc 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102973A2 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Martinex-Torrecuadrada J., et al: Clin Cancer Res, 2005, vol 11, no 17, pp 6280-6290 *
Wang W., et al: Eur J Cancer, 2008, vol 6, no 12, pp 63 *

Also Published As

Publication number Publication date
EA201170590A1 (ru) 2011-10-31
BRPI0919832A8 (pt) 2019-01-08
JP2012505912A (ja) 2012-03-08
US8404240B2 (en) 2013-03-26
WO2010048026A3 (en) 2010-07-15
MX2011004317A (es) 2011-06-24
CA2741127C (en) 2015-06-02
AU2009307841A1 (en) 2010-04-29
CN103524620A (zh) 2014-01-22
EA021584B1 (ru) 2015-07-30
EP2342232A2 (en) 2011-07-13
AR073770A1 (es) 2010-12-01
US20120009200A1 (en) 2012-01-12
CN102186884A (zh) 2011-09-14
US20120219563A1 (en) 2012-08-30
CN102186884B (zh) 2014-08-13
US8043618B2 (en) 2011-10-25
IL211807A0 (en) 2011-06-30
TW201026325A (en) 2010-07-16
WO2010048026A2 (en) 2010-04-29
TWI381848B (zh) 2013-01-11
UA101681C2 (ru) 2013-04-25
KR20110056554A (ko) 2011-05-30
NZ592369A (en) 2013-02-22
JP5577345B2 (ja) 2014-08-20
US20100098696A1 (en) 2010-04-22
ZA201101938B (en) 2012-08-29
KR101370798B1 (ko) 2014-03-14
BRPI0919832A2 (pt) 2015-12-15
CA2741127A1 (en) 2010-04-29
US8182815B2 (en) 2012-05-22

Similar Documents

Publication Publication Date Title
AU2009307841B2 (en) Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment
US20230406941A1 (en) Anti-AXL Antagonistic Antibodies
CN113321732B (zh) 抗axl抗体
CN113563471B (zh) 抗axl抗体
CN109311997B (zh) 抗axl拮抗抗体
JP2005500034A (ja) 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用
JP2021531825A (ja) 葉酸受容体アルファに特異的な抗体
KR102887692B1 (ko) 항-bcam 항체 또는 그의 항원 결합 단편
US20240336683A1 (en) Antibodies specific to sialic acid-binding ig-like lectin 15 and uses thereof
TW202330026A (zh) 用於療法之抗btn3a活化抗體及il2促效劑之組合
CN114685658B (zh) Ox40的靶向抗体及其制备方法和应用
KR20240126876A (ko) 항-βKlotho 항체 및 이의 응용

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired